LeMaitre Vascular (LMAT)
(Delayed Data from NSDQ)
$94.26 USD
+1.03 (1.10%)
Updated Aug 7, 2025 04:00 PM ET
After-Market: $94.37 +0.11 (0.12%) 5:32 PM ET
2-Buy of 5 2
D Value C Growth B Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, LeMaitre Vascular, Inc. has a PEG ratio of 2.59 compared to the Medical - Products industry's PEG ratio of 2.19.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
LMAT 94.26 +1.03(1.10%)
Will LMAT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LMAT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LMAT
LeMaitre Vascular (LMAT) Beats Q2 Earnings and Revenue Estimates
PAHC vs. LMAT: Which Stock Should Value Investors Buy Now?
LMAT: What are Zacks experts saying now?
Zacks Private Portfolio Services
LeMaitre Vascular (LMAT) Lags Q1 Earnings Estimates
BD Stock Down Despite Monitoring Platform Launch to Boost Patient Care
FitLife Brands (FTLF) Surges 13.1%: Is This an Indication of Further Gains?
Other News for LMAT
Decoding LeMaitre Vascular Inc (LMAT): A Strategic SWOT Insight
LeMaitre Vascular Breaks Above 200-Day Moving Average - Bullish for LMAT
LMAT: Cantor Fitzgerald Raises Price Target Amid Neutral Rating | LMAT Stock News
LMAT Upgraded to 'Outperform' by Barrington Research | LMAT Stock News
LeMaitre just upgraded at Barrington, here's why